Jing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Chen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Joann Diray-Arce
Harvard Medical School
3 shared publications - Ofer Levy
Precision Vaccines Program, Boston Children’s Hospital, Harvard Medical School, Boston, USA
3 shared publications - Annmarie Hoch
Clinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
2 shared publications - Caitlin Syphurs
Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA
2 shared publications - Hanno Steen
Boston Children's Hospital
2 shared publications - Ruth Rebecca Montgomery
Yale School of Medicine, New Haven, USA
2 shared publications
Latest Publications
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70428
Plasma metabolomics in infancy reveals early signatures of a stringently‐defined otitis‐prone phenotype
Background: Otitis media is highly prevalent during early life, yet the molecular factors that predispose children to recurrent episodes are poorly defined. Metabolomics captures dynamic biochemical changes and may help identify pathways influencing otitis susceptibility. We examined whether longitudinal infant plasma metabolomic profiles were associated with development of stringently‐defined otitis proneness in the Rochester Combined Cohort (RCC; Rochester, NY). Methods: Global plasma metabolomic profiling was performed in RCC samples collected between ~6 and 18 months of age using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Children were classified as stringently‐defined otitis prone (sOP) if they experienced ≥3 acute otitis media (AOM) episodes within a 6‐month period or ≥4 AOM episodes within a 12‐month period during the first 3 years of life; all AOM episodes were tympanocentesis‐confirmed. Generalized additive mixed models (GAMMs) assessed age‐dependent differences in plasma metabolite levels between sOP and non‐otitis‐prone (nOP) children, adjusting for potential confounders. Results: Several metabolites demonstrated age‐related declines in lipid and amino acid pathways, with consistently lower metabolite trajectories in the sOP group. Compared with nOP children, sOP children exhibited significantly lower levels of 16 metabolites related to inflammatory lipid signaling, redox metabolism, and fatty acid metabolism ( p < 4.4 × 10 −4 ) and higher levels of glycerophosphoinositol ( p = 2.9 × 10 −4 ). These findings were directionally consistent in a sensitivity analysis additionally adjusted for recent antibiotic use. Conclusion: Children who subsequently met sOP criteria by age 3 years exhibited distinct plasma metabolomic signatures during infancy, suggesting altered immune–metabolic programming preceding recurrent otitis media. Longitudinal metabolomics provides a promising framework to identify biochemical mechanisms underlying otitis proneness.
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70428
Plasma metabolomics in infancy reveals early signatures of a stringently‐defined otitis‐prone phenotype
Background: Otitis media is highly prevalent during early life, yet the molecular factors that predispose children to recurrent episodes are poorly defined. Metabolomics captures dynamic biochemical changes and may help identify pathways influencing otitis susceptibility. We examined whether longitudinal infant plasma metabolomic profiles were associated with development of stringently‐defined otitis proneness in the Rochester Combined Cohort (RCC; Rochester, NY). Methods: Global plasma metabolomic profiling was performed in RCC samples collected between ~6 and 18 months of age using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Children were classified as stringently‐defined otitis prone (sOP) if they experienced ≥3 acute otitis media (AOM) episodes within a 6‐month period or ≥4 AOM episodes within a 12‐month period during the first 3 years of life; all AOM episodes were tympanocentesis‐confirmed. Generalized additive mixed models (GAMMs) assessed age‐dependent differences in plasma metabolite levels between sOP and non‐otitis‐prone (nOP) children, adjusting for potential confounders. Results: Several metabolites demonstrated age‐related declines in lipid and amino acid pathways, with consistently lower metabolite trajectories in the sOP group. Compared with nOP children, sOP children exhibited significantly lower levels of 16 metabolites related to inflammatory lipid signaling, redox metabolism, and fatty acid metabolism ( p < 4.4 × 10 −4 ) and higher levels of glycerophosphoinositol ( p = 2.9 × 10 −4 ). These findings were directionally consistent in a sensitivity analysis additionally adjusted for recent antibiotic use. Conclusion: Children who subsequently met sOP criteria by age 3 years exhibited distinct plasma metabolomic signatures during infancy, suggesting altered immune–metabolic programming preceding recurrent otitis media. Longitudinal metabolomics provides a promising framework to identify biochemical mechanisms underlying otitis proneness.
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Virus reactivation in acute and long COVID-19
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Open AccessVirus reactivation in acute and long COVID-19
- Open Access
- 18 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
MTHFR allele and one-carbon metabolic profile predict severity of COVID-19
While the public health burden of SARS-CoV-2 infection has lessened due to natural and vaccine-acquired immunity, emergence of less virulent variants, and antiviral medications, COVID-19 continues to take a significant toll. There are thousands of new hospitalizations and hundreds of deaths per week in the United States, many of whom develop long COVID. Early identification of individuals at high risk of severe COVID-19 is key for monitoring and supporting respiratory status and improving outcomes. Therefore, precision tools for early detection of patients at high risk of severe disease can reduce morbidity and mortality. Here, we report an untargeted, longitudinal plasma metabolomics study of COVID-19 patients. One-carbon metabolism, a pathway previously shown as critical for viral propagation and disease progression, and a potential target for COVID-19 treatment, scored strongly as differentially abundant in patients with severe COVID-19. Targeted metabolite profiling revealed that one arm of the one-carbon metabolism pathway, the methionine cycle, is a major driver of the metabolic profile associated with disease severity. Further, genomic data from the profiled patients revealed a genetic contributor to methionine metabolism and identified the C677T allele of the MTHFR gene as a preexisting contributor to disease trajectory—patients that show aberrant one-carbon metabolite levels and that are homozygous for the MTHFR C677T, have higher incidence of severe COVID. Our results raise the possibility that MTHFR variant status may inform precision COVID-19 treatment strategies.
- 18 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
Open AccessMTHFR allele and one-carbon metabolic profile predict severity of COVID-19
While the public health burden of SARS-CoV-2 infection has lessened due to natural and vaccine-acquired immunity, emergence of less virulent variants, and antiviral medications, COVID-19 continues to take a significant toll. There are thousands of new hospitalizations and hundreds of deaths per week in the United States, many of whom develop long COVID. Early identification of individuals at high risk of severe COVID-19 is key for monitoring and supporting respiratory status and improving outcomes. Therefore, precision tools for early detection of patients at high risk of severe disease can reduce morbidity and mortality. Here, we report an untargeted, longitudinal plasma metabolomics study of COVID-19 patients. One-carbon metabolism, a pathway previously shown as critical for viral propagation and disease progression, and a potential target for COVID-19 treatment, scored strongly as differentially abundant in patients with severe COVID-19. Targeted metabolite profiling revealed that one arm of the one-carbon metabolism pathway, the methionine cycle, is a major driver of the metabolic profile associated with disease severity. Further, genomic data from the profiled patients revealed a genetic contributor to methionine metabolism and identified the C677T allele of the MTHFR gene as a preexisting contributor to disease trajectory—patients that show aberrant one-carbon metabolite levels and that are homozygous for the MTHFR C677T, have higher incidence of severe COVID. Our results raise the possibility that MTHFR variant status may inform precision COVID-19 treatment strategies.